|
|
CAF04 |
|
Vaxjo ID |
294 |
|
Vaccine Adjuvant Name |
CAF04 |
|
Alternative Names |
The synonym for CAF04 is "cationic adjuvant formulation 04." |
|
Adjuvant VO ID |
VO_0005659
|
|
Description |
CAF04 is a cationic liposomal vaccine adjuvant primarily used to enhance immune responses to vaccines, particularly for tuberculosis and Chlamydia vaccines. |
|
Stage of Development |
Clinical Trial |
|
Host Species for Testing |
Human |
|
Structure |
The specific structure of CAF04 is not detailed in the article, but it consists of cationic lipids (such as dimethyldioctadecylammonium) and other components. |
|
Function |
The quality and magnitude of the elicited immune responses were determined after vaccination of CB6/F1 mice using the Chlamydia trachomatis major outer membrane protein (MOMP) as antigen. MMG-1-based hexosomes potentiated significantly stronger MOMP-specific humoral responses than CAF04 liposomes |
| References |
Rodrigues et al., 2018: Rodrigues L, Raftopoulos KN, Tandrup Schmidt S, Schneider F, Dietz H, Rades T, Franzyk H, Pedersen AE, Papadakis CM, Christensen D, Winter G, Foged C, Hubert M. Immune responses induced by nano-self-assembled lipid adjuvants based on a monomycoloyl glycerol analogue after vaccination with the Chlamydia trachomatis major outer membrane protein. Journal of controlled release : official journal of the Controlled Release Society. 2018; 285; 12-22. [PubMed: 29964134].
|
|
